{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-006993","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.673520+00:00","generated_at":"2026-05-16T11:12:53.119833+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"confidence":"high","headline":"Indivior provides FY2026 guidance: revenue $1.125B-$1.195B, Adj. EBITDA $535M-$575M","bullets":["Total net revenue expected $1,125M-$1,195M; SUBLOCADE net revenue $905M-$945M.","Non-GAAP operating expenses guided at $430M-$450M; adjusted EBITDA $535M-$575M.","Completed Phase I of Indivior Action Agenda with annual operating expense savings of at least $150M.","Shareholders approved U.K. to U.S. domicile change; expected effective Jan 26, 2026.","Concluded DOJ matter by paying $295M in full; entered Phase II focused on accelerating growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-006993","json":"https://secwatch.observer/filing/0001193125-26-006993.json","markdown":"https://secwatch.observer/filing/0001193125-26-006993.md","text":"https://secwatch.observer/filing/0001193125-26-006993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526006993/0001193125-26-006993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526006993/d74661d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:12:53.119833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}